MilliporeSigma Expands Biodevelopment CentersBy
MilliporeSigma, the life science business of Merck KGaA, has expanded its biodevelopment centers for its portfolio of bioprocessing products, manufacturing capabilities, and technological expertise.
The expansion includes the opening of two new process development centers in Boston, Massachusetts and Shanghai, China and follows the commercial launch of MilliporeSigma’s biodevelopment center in Martillac, France. Each new center will provide a process-development capabilities and services, including cell-line development services, both upstream and downstream process development as well as non-GMP clinical production. MilliporeSigma’s biodevelopment center in Martillac, France, is a single-use, GMP facility for manufacturing clinical stage batches and is equipped with a 2,000 liter single-use bioreactor.